Although ZOL-FO provides clinical benefits for patients with CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma, its high cost limits its widespread use. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.